SAN DIEGO and EVRY, France, Dec. 16 /PRNewswire/ -- Privately held biotechnology companies, SGX (Structural GenomiX, Inc.) and UroGene S.A., of France, today announced that they have formed a joint research and development collaboration for the discovery and clinical development of novel drugs for the treatment of urological cancers. Under the terms of the agreement, SGX and UroGene will jointly develop small molecule inhibitors against novel urological cancer kinase targets. The SGX FAST(TM) (Fragments of Active STructures) lead discovery technology will be combined with UroGene's expertise in target validation and clinical studies for urological indications to initially focus on the development of drugs for the treatment of bladder cancer. Bladder cancer is the sixth most commonly diagnosed malignancy in the United States and Europe, with approximately 60,000 and 90,000 new cases diagnosed during 2002 in the US and the EU, respectively. It is estimated that over two million patients worldwide are living with bladder cancer. SGX will have exclusive commercialization rights in North America to drugs developed under the collaboration, while UroGene will have exclusive commercialization rights within Europe.
"We are excited to be joining forces with UroGene in seeking to address the important unmet medical needs in urological cancer," said Stephen K. Burley, M.D., D.Phil., CSO of SGX. "In combining SGX's expertise in lead discovery with UroGene's deep understanding of the biology of urological drug targets and extensive clinical network, our companies are well positioned to rapidly advance the development of therapeutic products in this area."
"Bladder cancer has a high rate of recurrence, characterized by aggressive tumors and a poor prognosis. Current therapies for bladder cancer and recurrent episodes deserve major improvement both in terms of increasing efficacy and decreasing side effects," stated Dr. Hugues Bienayme, PhD, CSO of UroGene. "UroGene has discovered and validated kinase targets that are very promising for the development of new and effective therapeutic agents in this field. Collaborating with SGX to apply their cutting-edge FAST(TM) lead discovery technology on our kinase targets represents a significant benefit towards the development of potent anti-cancer drugs."
SGX is a structure guided drug discovery company accelerating the discovery of novel therapeutics to treat human diseases. SGX has developed FAST(TM), a proprietary technology for rapid identification of novel, potent and selective small molecule inhibitors of drug targets. FAST(TM) relies on libraries of synthetically enabled fragments developed by SGX, to ensure rapid hit-to-lead optimization and draws on SGX expertise in high-throughput co- crystallography, state of the art computational scoring and automated parallel synthesis. SGX technology drives the lead optimization process through iterative determination of co-crystal structures that reveal, in atomic detail, how small molecules interact with drug targets. The Company has established unparalleled capacity in this area by building SGX-CAT, a world- class facility for the collection of macromolecular X-ray diffraction data at the Advanced Photon Source (APS), located at the U.S. Department of Energy Argonne National Laboratory. SGX utilizes FAST(TM) on programs focused in oncology as well as partnered programs in other disease areas. The Company is based in San Diego, California. For more information, please visit our website at http://www.stromix.com/ .
UroGene is a drug discovery and development company. The Company was founded in 1998 by leading clinicians and scientists in the field of urology to enable the discovery and development of new therapies for this large and unaddressed market. UroGene's corporate headquarters as well as its biological research facilities are located in Evry Genopole, France's national Biotechnology Science and Business Park, and its chemistry research facilities are located in Lyon, France. A representative office is located in Cambridge, MA, USA. By accessing highly annotated prostate and bladder tissues from its clinical network, UroGene's scientists have discovered, validated and developed innovative drug targets. UroGene has also developed an unique chemistry-driven strategy and expertise to deliver small molecule chemotherapeutics on those targets. The company is currently developing four internal projects dedicated to find new cures for various stages of prostate and bladder cancer. UroGene's business model is based on a combination of innovative internal research programs as well as targeted and high quality in licensing compounds at late preclinical or early clinical stages in urological indications. For more information please visit our web site at http://www.urogene.com/ .
This press release contains forward-looking statements that may relate to future events or SGX's future performance. We cannot guarantee future events or performance, which may differ materially from our expectations. We urge you to carefully review and consider the various disclosures made by us that describe some of the factors that affect our business and may cause such material differences.
SGX; UroGene S.A.
CONTACT: Herbert G. Mutter, Vice President, Finance, of SGX,+1-858-228-1565, firstname.lastname@example.org; or Jason Spark of Atkins +Associates, +1-858-527-3491, email@example.com, for SGX; or Marie-LaureBouttier, Communication, +(011 33) 1 60 87 89 80, firstname.lastname@example.org, orPierre Belichard, Vice President, Business Development,+(011 33) 1 60 87 89 80, email@example.com, both of UroGene S.A.